Immunodiagnostic Systems (IDS) is a global medical diagnostics business dedicated to the development and provision of innovative automated and manual assays. The Company's development focus is in the clinical areas of bone and calcium metabolism, growth, hypertension and chronic kidney disease. Its IDS-iSYS system is designed with the flexibility to accommodate unique and challenging requirements, the IDS-iSYS automation brings testing efficiency and uncompromised quality to specialty immunoassay testing. IDS provides a compact bench top system that fully automates immunoassay testing. IDS has its global headquarters in the UK, and has subsidiaries in the USA, Germany, France, and Denmark. Other markets, including key diagnostic markets of Spain, Italy, Australia, and Japan, are serviced by a network of highly qualified and experienced distributors within each territory.

Boldon, GB
Size (employees)
275 (est)
Immunodiagnostic Systems was founded in 1977 and is headquartered in Boldon, GB
Report incorrect company information

Key People/Management at Immunodiagnostic Systems

Regis Duval

Regis Duval

Chief Executive Officer

Immunodiagnostic Systems Office Locations

Immunodiagnostic Systems has offices in Frankfurt, Gaithersburg, Boldon, Copenhagen and in 1 other location
Boldon, GB (HQ)
10 Didcot Way
Show all (5)
Report incorrect company information

Immunodiagnostic Systems Financials and Metrics

Immunodiagnostic Systems Financials

Immunodiagnostic Systems's revenue was reported to be £40.04 m in FY, 2017

Revenue (FY, 2017)

40 m

Gross profit (FY, 2017)

23 m

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

3 m

EBITDA (FY, 2017)

6.3 m

EBIT (FY, 2017)

1.7 m

Market capitalization (31-Oct-2017)

84.6 m

Closing share price (31-Oct-2017)


Cash (31-Mar-2017)

31.5 m
Immunodiagnostic Systems's current market capitalization is £84.6 m.
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


18.7 m24.9 m37.2 m50.2 m53.7 m49.8 m52.3 m45.4 m38.3 m40 m

Revenue growth, %


Cost of goods sold

7.2 m8.4 m9.6 m12.7 m13.6 m13.4 m16.7 m17 m15.8 m17.1 m

Gross profit

11.4 m16.6 m27.5 m37.5 m40.1 m36.4 m35.6 m28.3 m22.5 m23 m
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


3 m4.5 m5.3 m6.4 m11 m19.6 m26.7 m23.7 m26.6 m31.5 m

Accounts Receivable

4 m4.4 m6.4 m7.8 m3.6 m7.3 m5.2 m5.4 m5.3 m6.7 m


6.2 m5.7 m6.4 m8.5 m7.5 m5.9 m6.5 m6.8 m7.5 m7.6 m

Current Assets

14 m19.4 m23.2 m27.8 m27.4 m35.9 m42.5 m40.7 m43.2 m48.9 m
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

2.8 m4.2 m8.1 m12.9 m4.7 m7.8 m7 m2.4 m(32.2 m)3 m

Cash From Operating Activities

445 k5.3 m9.7 m16.5 m14.3 m18.4 m12.3 m8.8 m8.2 m8.4 m

Dividends Paid

202 k360.3 k436.3 k559 k708 k215 k866 k2.5 m876 k353 k

Cash From Financing Activities

24.9 m1.9 m(1.9 m)(5.5 m)(2.1 m)(5 m)854 k(2.6 m)(985 k)(537 k)
GBPY, 2017


132.8 k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information